Home page Home page

Xagrid
anagrelide

Package leaflet: Information for the patient


Xagrid 0.5 mg hard capsules

anagrelide


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.



Reporting of side effects


image

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

  1. How to store Xagrid


    Keep this medicine out of the sight and reach of children.


    Do not use this medicine after the expiry date which is stated on the carton and bottle label after EXP. The expiry date refers to the last day of that month.


    This medicine does not require any special storage conditions.


    If your doctor stops your medicine, do not keep any leftover capsules unless your doctor tells you to. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.


  2. Contents of the pack and other information What Xagrid contains

The active substance is anagrelide. Each capsule contains 0.5 mg anagrelide (as anagrelide hydrochloride).


The other ingredients are:

Capsule contents: povidone (E1201); crospovidone; lactose, anhydrous; lactose monohydrate; cellulose, microcrystalline (E460) and magnesium stearate.

Capsule shell: gelatin and titanium dioxide (E171).

Printing ink: shellac; strong ammonium solution; potassium hydroxide (E525); black iron oxide (E172).


What Xagrid looks like and contents of the pack


Xagrid is supplied as opaque, white, hard capsules. They are marked with ‘S 063’.

The capsules are provided in bottles containing 100 hard capsules. The bottle also contains a small sealed container. This contains a drying agent to keep the capsules dry. Keep the sealed container in

the bottle. Do not remove or eat the drying agent.


Marketing Authorisation Holder and Manufacturer


Takeda Pharmaceuticals International AG Ireland Branch Block 3 Miesian Plaza

50 – 58 Baggot Street Lower

Dublin 2 Ireland

Tel: +800 66838470

E-mail: medinfoEMEA@takeda.com


This leaflet was last revised in.


. There are also links to other websites about rare diseases and treatments.